Biotechnology News 7 December 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low

9 December 2025

Biotechnology·FDA News·Investment Insights·Market Trends·Stock Analysis

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering

9 December 2025

Biotechnology·Healthcare News·Investment·Pharmaceutical Industry·Stock Market

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after

9 December 2025

Analyst Forecasts·Biotechnology·Pharmaceutical Industry·Stock News

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. (NASDAQ: IBIO) has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again

9 December 2025

Biotechnology·Investment News·Market Analysis·Stocks

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about

9 December 2025

Biotechnology·Investment News·Pharmaceutical Industry·Stock Market

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. (NYSE: PFE) is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade

8 December 2025

Biotechnology·Financial News·Pharmaceuticals·Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007.

8 December 2025

Biotechnology·Investment·Stocks·Wall Street

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor

8 December 2025

Analyst Insights·Biotechnology·Investment News·Pharmaceutical Industry·Stock Market

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something

8 December 2025

Artificial Intelligence·Biotechnology·Clinical Trials·Pharmaceuticals·Stock Analysis

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

Market data in this article are as of December 8, 2025, 09:13 UTC. Where SLS Stock Stands Today SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is trading at around $1.74 per share in early trading on December 8, 2025, barely

8 December 2025

Analyst Ratings·Biotechnology·Financial News·Investment Analysis·Stock Market

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know

8 December 2025

Biotechnology·Financial News·Investing·Stock Market

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX

7 December 2025

Biotechnology·Investment Analysis·Pharmaceuticals·Stock Market

Biotechnology News 7 December 2025 - 9 December 2025